NAARDEN, The Netherlands—April 2, 2007—Building on their earlier collaboration with GE Healthcare, BAC BV announced it will develop its CaptureSelect affinity ligands to create an affinity chromatography medium for the capture of therapeutic recombinant FVIII. The protein is used in the prevention and treatment of bleeding in patients with Hemophilia A.
CHALFONT ST. GILES, U.K.—GE Healthcare and Unilever spin-off BAC NV announced a strategic collaboration that will see the companies develop new affinity ligands and chromatographic media for the purification of human antibodies and adeno-associated virus (AAV) viral vectors. The collaboration will focus on BAC's CaptureSelect portfolio, which is based on single-domain antibody fragments produced in yeast.
"This collaboration will allow us to expand our current range of ligand technologies and libraries, enabling us to develop more efficient purification processes for our customers in biopharmaceutical manufacturing," said Ann O'Hara, GE general manager of bioprocess.
Financial details were not provided, but the first products are expected to be available in 2007 and will be distributed through GE Healthcare's Custom Designed Media business.